Market open

Dyne Therapeutics/$DYN

14:30

22:10

05:45

13:25

21:00

1D1W1MYTD1Y5YMAX

About Dyne Therapeutics

Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.

Ticker

$DYN

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Waltham, United States

Employees

173

Website

www.dyne-tx.com

DYN Metrics

BasicAdvanced

$1.5B

-

-$3.51

1.10 -

Price and volume

Market cap

$1.5B

Beta

1.1

52-week high

$47.45

52-week low

$14.79

Average daily volume

1.3M

Financial strength

Current ratio

17.022

Quick ratio

16.728

Long term debt to equity

2.841

Total debt to equity

3.523

Management effectiveness

Return on assets (TTM)

-40.35%

Return on equity (TTM)

-68.69%

Valuation

Price to book

2.16

Price to tangible book (TTM)

2.16

Price to free cash flow (TTM)

-5.154

Growth

Earnings per share change (TTM)

-3.06%

3-year earnings per share growth (CAGR)

11.10%

What the Analysts think about DYN

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Dyne Therapeutics stock.

DYN Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

DYN Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

DYN News

AllArticlesVideos

Why Is Neuromuscular-Focused Dyne Therapeutics Stock Trading Lower On Friday?

Benzinga·5 days ago

Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026

GlobeNewsWire·5 days ago

Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewsWire·6 days ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $DYN

$

Capital at risk

Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Dyne Therapeutics stock?

Dyne Therapeutics (DYN) has a market cap of $1.5B as of January 15, 2025.

What is the P/E ratio for Dyne Therapeutics stock?

The price to earnings (P/E) ratio for Dyne Therapeutics (DYN) stock is 0 as of January 15, 2025.

Does Dyne Therapeutics stock pay dividends?

No, Dyne Therapeutics (DYN) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Dyne Therapeutics dividend payment date?

Dyne Therapeutics (DYN) stock does not pay dividends to its shareholders.

What is the beta indicator for Dyne Therapeutics?

Dyne Therapeutics (DYN) has a beta rating of 1.1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.